Gemcitabine plus nab-paclitaxel versus gemcitabine alone in elderly patients aged 76 years or older with unresectable pancreatic cancer: A propensity score-matched multicenter prospective observational study.

Satoshi Kobayashi,Motoko Suzuki,Makoto Ueno,Yuta Maruki,Junji Furuse,Akiko Todaka,Masato Ozaka,Kunihiro Tsuji,Kazuhiko Shioji,Keitaro Doi,Yasushi Kojima,Hidetaka Tsumura,Kazunari Tanaka,Hajime Higuchi,Ken Kawabe,Takeharu Yamanaka,Hiroshi Ishii

Gemcitabine plus nab-paclitaxel versus gemcitabine alone in elderly patients aged 76 years or older with unresectable pancreatic cancer: A propensity score-matched multicenter prospective observational study.

2021

Satoshi Kobayashi
Motoko Suzuki
Makoto Ueno
Yuta Maruki
Junji Furuse
Akiko Todaka
Masato Ozaka
Kunihiro Tsuji
Kazuhiko Shioji
Keitaro Doi
Yasushi Kojima
Hidetaka Tsumura
Kazunari Tanaka
Hajime Higuchi
Ken Kawabe
Takeharu Yamanaka
Hiroshi Ishii

4123Background: Gemcitabine plus nab-paclitaxel (GN) demonstrated a significant improvement of OS over gemcitabine alone (G) in the MPACT trial for metastatic pancreatic cancer. However, since pati...

Keywords:

Gemcitabine
Internal medicine
Medicine
Oncology
Observational study
Unresectable Pancreatic Cancer
Nab-paclitaxel
Propensity score matching
Metastatic pancreatic cancer

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations